Nonalcoholic fatty liver disease pharmacotherapy: accent on fibrosis

Cover Page

Cite item

Full Text

Abstract

Study objective - to evaluate taurin effect on liver fibrosis severity, structural and functional liver characteristics in patients with nonalcoholic fatty liver disease (NAFLD). Materials and methods. The prospective comparative randomized study included 60 patients with NAFLD diagnosed according to liver ultrasound results (using SIEMENS SONOLINE G50, Germany system with doppler sensor for liver parenchymal echogenicity, vascular pattern, and echoed signal decrement evaluation) and liver fibrosis index NFS>0.675 (F3-4 fibrosis). With the use of simple randomization patients were divided into 2 groups: group 1 (study group) included patients with NAFLD who received taurin in total daily dose 1000 mg (500 mg twice a day) in addition to comorbid conditions (diabetes mellitus type 2, ischemic heart disease, hypertension) treatment; group 2 (control group) included patients with NAFLD who received only comorbid conditions treatment. Type IV collagen serum level, fatty liver index (FLI), and NAFLD fibrosis score (NFS) were evaluated at baseline and after 24 weeks of treatment. Сarbohydrate metabolism parameters were monitored by fasting plasma glucose level, basal insulin level and insulin resistance index (HOMA-IR) evaluation. For lipid metabolism monitoring total cholesterol, triglyceride, low-density lipoprotein, and high-density lipoprotein levels were evaluated. For damage and functional liver markers assessment alanine and aspartate aminotransferase, g-glutamyl transpeptidase activity was evaluated. Results. After 24 weeks of treatment with taurin a statistically significant decrease in type IV collagen level, and NFS decrease on all stages of fibrotic changes that was statistically significant on early fibrosis stages (NFS≤0.675) were observed in patients with NAFLD and liver fibrosis. A significant metabolic activity of the drug was shown that presented with hypoglycemic and lipid-lowering effects as well as significant insulin resistance reduction.

About the authors

M. E Statsenko

Volgograd State Medical University of Ministry of Health of the Russian Federation

Email: mestatsenko@rambler.ru
д-р мед. наук, проф., зав. каф. внутренних болезней педиатрического и стоматологического фак-товг 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1

S. V Turkina

Volgograd State Medical University of Ministry of Health of the Russian Federation

д-р мед. наук, проф. каф. внутренних болезней педиатрического и стоматологического фак-тов 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1

N. N Shilina

Volgograd State Medical University of Ministry of Health of the Russian Federation

ассистент каф. внутренних болезней педиатрического и стоматологического фак-тов 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1

E. E Gorbachev

Volgograd State Medical University of Ministry of Health of the Russian Federation

аспирант каф. внутренних болезней педиатрического и стоматологического фак-тов 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1

A. A Ermolenko

Volgograd State Medical University of Ministry of Health of the Russian Federation

аспирант каф. внутренних болезней педиатрического и стоматологического фак-тов 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1

References

  1. Younossi Z.M, Koenig A.B, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
  2. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлиническоий практики в Российской̆ Федерации: результаты исследования DIREG 2. РЖГГК. 2015; 6: 31-42.
  3. Patil R, Sood G.K. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol 2017; 8 (2): 51-8.
  4. Arulanandan A, Ang B, Bettencourt R et al. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2015; 13: 1513-20.
  5. Sö̈derberg C, Stȧl P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
  6. Sinn D.H, Kang D, Jang H.R et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. J Hepatol 2017; 67 (6): 274-1280.
  7. Lonardo A, Ballestri S, Guaraldi G et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22 (44): 9674-93.
  8. Ekstedt M, Hagstrom H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-54.
  9. Hagström H, Nasr P, Ekstedt M et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017; 67 (6): 1265-73.
  10. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. European Association for the Study of the Liver (EASL) & European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). Diabetologia 2016; 59: 1121-40.
  11. Weiskirchen R. Hepatoprotective and Anti-fibrotic Agents: It’s Time to Take the Next Step. Front Pharmacol 2015; 6: 303-43.
  12. Schaffer S.W, Azuma J, Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 2009; 87 (2): 91-9.
  13. Barua M, Liu Y, Quinn M.R. Taurine chloramine inhibits inducible nitric oxide synthase and TNF-alpha gene expression in activated alveolar macrophages: decreased NF-kappaB activation and IkappaB kinase activity. J Immunol 2001; 167 (4): 2275-81.
  14. Li M, Reynolds C.M, Sloboda D.M et al. Effects of Taurine Supplementation on Hepatic Markers of Inflammation and Lipid Metabolism in Mothers and Offspring in the Setting of Maternal Obesity. PLoS One 2013; 8 (10): e769.
  15. Abdel-Moneim A.M, Al-Kahtani M.A, El-Kersh M.A, Al-Omair M.A. Free Radical- Scavenging, Anti-Inflammatory/Anti-Fibrotic and Hepatoprotective Actions of Taurine and Silymarin against CCl4 Induced Rat Liver Damage. PLoS One 2015; 10 (12): e0144509.
  16. De la Puerta C, Arrieta F.J, Balsa J.A et al. Taurine and glucose metabolism: a review. Nutr Hosp 2010; 25: 910-9.
  17. Militante J.D, Lombardini J.B. Dietary taurine supplementation: hypolipidemic and antiatherogenic effects. Nutr Res 2004; 24: 787-801.
  18. Putnam K, Shoemaker R, Yiannikouris F, Cassis L.A. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 30: H1219-1230.
  19. Нano T, Kasano M, Tomari H, Iwane N. Taurine suppresses pressor response through the inhibition of sympathetic nerve activity and the improvement in baro-reflex sensitivity of spontaneously hypertensive rats. Adv Exp Med Biol 2009; 643: 57-63.
  20. Ergü̈n Yílmaz. The diagnostic role of ultrasonograhyy in liver streatosis. Turkish J Gastroenterol 1999; 2: 96-100.
  21. Angulo P, Hui J.M, Marchesini G et al. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hеpatology 2007; 45 (4): 846-54.
  22. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006; 6: 33-8.
  23. Стаценко М.Е., Туркина С.В., Шилина Н.Н. Поражение печени у больных с хронической сердечной недостаточностью ишемического генеза и сахарным диабетом типа 2 - коварный тандем: возможности дополнительной органопротективной терапии. Consilium Medicum. 2016; 18 (5): 103-9.
  24. Morling J.R, Fallowfield J.A, Williamson R.M et al. y-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. Diabetologia 2015; 58: 1484-93.
  25. Gentile C.L, Nivala A.M, Gonzales J.C et al. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Regul Integr Comp Physiol. 2011; 301 (6): 1710-22.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies